Novo Nordisk said the Food and Drug Administration approved the diabetes-drug Ozempic to be used to help kidney-disease patients. Ozempic, or semaglutide, can now be used to reduce the risk of ...
Medicare added Novo Nordisk's Ozempic, Wegovy, and Rybelsus to its 2027 drug price negotiations list. This move could force Novo Nordisk to slash the costs of its top drugs. The company should ...
Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said on Wednesday its net profit jumped 21 per cent in 2024 to 100 billion Danish ...
Der er noget nær reklamekrig mellem medicinalfirmaer i USA, og danske Novo Nordisk er endt midt i kampens hede.
Novo Nordisk stock gained, lifted by strong sales growth and guidance from the maker of Wegovy and Ozempic. Shares in Novo, ...
The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be targeted under legislation that’s expected save the government more than ...
Novo Nordisk has been one of the chief beneficiaries ... build on the success of flagship weight-loss treatments Wegovy and Ozempic. Like those injections, the new drug targets gut hormone GLP ...
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year. By Eshe Nelson Reporting from London Novo Nordisk ...
While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more convenient option: A pill. Novo Nordisk already makes semaglutide ...
Few drugs have generated as much excitement as Novo Nordisk's (NYSE: NVO) Ozempic and Wegovy. The U.S. Food and Drug Administration (FDA) approved Ozempic in December 2017 for treating type 2 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results